类风湿关节炎患者的共病聚类识别出预后良好的患者表型
基于人群研究纳入2015年1月1日八县地区1643例现患类风湿关节炎患者,用潜类别分析按55种共病聚类并随访至2021年12月31日。识别出4个聚类,聚类1患者合并症少、缓解更多且死亡率与一般人群相当;预后最差的聚类(占现患类风湿关节炎患者<10%)年龄更大、共病更多、改善病情抗风湿药和生物制剂使用较少。
要点
- 共病聚类可区分类风湿关节炎患者的疾病活动度和生存差异。
- 聚类1合并症少,缓解更多,死亡率与一般人群相当。
- 预后最差的聚类占现患类风湿关节炎患者<10%,年龄更大、共病更多、改善病情抗风湿药和生物制剂使用较少。
核心结论
- 超过40%的现患类风湿关节炎患者死亡率不差于无类风湿关节炎的同类人群。
- 预后最差的聚类(占现患类风湿关节炎患者<10%)年龄更大、共病更多,且改善病情抗风湿药和生物制剂使用较其他聚类少。
- 共病模式可能是超越类风湿关节炎预后一刀切视角的关键。
研究设计与样本
- 基于人群的研究,识别2015年1月1日八县地区现患类风湿关节炎居民,随访至死亡、末次接触或2021年12月31日。
- 使用 prevalence date 前5年的诊断编码定义55种共病,采用潜类别分析按共病模式对患者聚类,用标准化死亡率比评估死亡率。
- 共纳入1643例现患类风湿关节炎患者(72%女性;94%白人;中位年龄64岁,中位类风湿关节炎病程7年)。
主要发现
- 识别出4个聚类:聚类1(n=686)合并症少;聚类4(n=134)为年龄较大且合并10种及以上共病的患者。
- 聚类2(n=200)为合并5种及以上共病且抑郁和肥胖患病率高的患者;聚类3(n=623)为其余患者。
- 各聚类间类风湿关节炎疾病活动度和生存存在差异,聚类1缓解更多且死亡率与一般人群相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to cluster patients with rheumatoid arthritis (RA) based on comorbidities and then examine the association between these clusters and RA disease activity and mortality. METHODS: In this population-based study, residents of an eight-county region with prevalent RA on 1 January 2015 were identified. Patients were followed for vital status until death, last contact or 31 December 2021. Diagnostic codes for 5 years before the prevalence date were used to define 55 comorbidities. Latent class analysis was used to cluster patients based on comorbidity patterns. Standardised mortality ratios were used to assess mortality. RESULTS: A total of 1643 patients with prevalent RA (72% female; 94% white; median age 64 years, median RA duration 7 years) were studied. Four clusters were identified. Cluster 1 (n=686) included patients with few comorbidities, and cluster 4 (n=134) included older patients with 10 or more comorbidities. Cluster 2 (n=200) included patients with five or more comorbidities and high prevalences of depression and obesity, while cluster 3 (n=623) included the remainder. RA disease activity and survival differed across the clusters, with cluster 1 demonstrating more remission and mortality comparable to the general population. CONCLUSIONS: More than 40% of patients with prevalent RA did not experience worse mortality than their peers without RA. The cluster with the worst prognosis (<10% of patients with prevalent RA) was older, had more comorbidities and had less disease-modifying antirheumatic drug and biological use compared with the other clusters. Comorbidity patterns may hold the key to moving beyond a one-size-fits-all perspective of RA prognosis.
引用
- Crowson CS, Atkinson EJ, Kronzer VL, et al. Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis. Ann Rheum Dis. 2024. PMID: 38331589. doi:10.1136/ard-2023-225093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。